Zentalis Pharmaceuticals (ZNTL) Competitors $1.42 +0.05 (+3.65%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZNTL vs. ERAS, SANA, ZVRA, ALT, SNDL, ORKA, KMDA, RVNC, TECX, and AUTLShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Erasca (ERAS), Sana Biotechnology (SANA), Zevra Therapeutics (ZVRA), Altimmune (ALT), SNDL (SNDL), Oruka Therapeutics (ORKA), Kamada (KMDA), Revance Therapeutics (RVNC), Tectonic Therapeutic (TECX), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Zentalis Pharmaceuticals vs. Erasca Sana Biotechnology Zevra Therapeutics Altimmune SNDL Oruka Therapeutics Kamada Revance Therapeutics Tectonic Therapeutic Autolus Therapeutics Erasca (NASDAQ:ERAS) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Which has stronger valuation and earnings, ERAS or ZNTL? Erasca has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Erasca is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$125.04M-$0.74-1.97Zentalis Pharmaceuticals$67.43M1.51-$292.19M-$2.32-0.61 Is ERAS or ZNTL more profitable? Erasca's return on equity of -42.26% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -42.26% -34.97% Zentalis Pharmaceuticals N/A -43.91%-34.96% Does the MarketBeat Community believe in ERAS or ZNTL? Zentalis Pharmaceuticals received 32 more outperform votes than Erasca when rated by MarketBeat users. However, 75.00% of users gave Erasca an outperform vote while only 62.00% of users gave Zentalis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformErascaOutperform Votes3075.00% Underperform Votes1025.00% Zentalis PharmaceuticalsOutperform Votes6262.00% Underperform Votes3838.00% Do analysts recommend ERAS or ZNTL? Erasca currently has a consensus price target of $4.83, indicating a potential upside of 231.05%. Zentalis Pharmaceuticals has a consensus price target of $8.24, indicating a potential upside of 480.59%. Given Zentalis Pharmaceuticals' higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Zentalis Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Do institutionals & insiders have more ownership in ERAS or ZNTL? 67.8% of Erasca shares are owned by institutional investors. 21.5% of Erasca shares are owned by company insiders. Comparatively, 3.6% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, ERAS or ZNTL? Erasca has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Does the media favor ERAS or ZNTL? In the previous week, Erasca had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 10 mentions for Erasca and 8 mentions for Zentalis Pharmaceuticals. Erasca's average media sentiment score of 1.08 beat Zentalis Pharmaceuticals' score of 0.80 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryErasca beats Zentalis Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$101.97M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-0.577.4522.4218.48Price / Sales1.51242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book0.236.516.774.25Net Income-$292.19M$143.21M$3.22B$248.23M7 Day Performance-5.33%3.97%3.26%3.29%1 Month Performance-21.55%0.37%0.02%2.42%1 Year Performance-87.16%2.60%18.01%5.54% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals1.9358 of 5 stars$1.42+3.6%$8.24+480.6%-87.2%$101.97M$67.43M-0.57160Upcoming EarningsNews CoverageERASErasca3.1291 of 5 stars$1.40+0.7%$4.83+245.2%-27.4%$396.57MN/A-1.69120Analyst ForecastPositive NewsSANASana Biotechnology1.9014 of 5 stars$1.76-0.6%$10.80+513.6%-78.9%$396.04MN/A-1.26380Upcoming EarningsZVRAZevra Therapeutics2.7749 of 5 stars$7.20flat$22.29+209.5%+60.0%$393.69M$23.61M-3.6520Upcoming EarningsNews CoveragePositive NewsALTAltimmune2.6578 of 5 stars$5.06-0.2%$20.83+311.7%-19.8%$389.69M$20,000.00-3.2650Upcoming EarningsNews CoveragePositive NewsSNDLSNDL2.8848 of 5 stars$1.47-1.3%$3.63+146.6%-39.7%$386.28M$920.45M-4.74580ORKAOruka Therapeutics3.1746 of 5 stars$10.28+1.9%$39.86+287.7%N/A$384.89MN/A-1.64N/AAnalyst RevisionNews CoveragePositive NewsKMDAKamada3.8825 of 5 stars$6.64-0.7%$14.67+120.9%+23.9%$381.67M$160.95M23.71360Upcoming EarningsShort Interest ↓RVNCRevance Therapeutics2.0952 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Upcoming EarningsAnalyst ForecastTECXTectonic Therapeutic2.5591 of 5 stars$20.18-4.3%$72.40+258.8%N/A$376.62MN/A-3.43120Upcoming EarningsShort Interest ↑AUTLAutolus Therapeutics2.6974 of 5 stars$1.39+4.5%$9.32+570.5%-61.7%$369.87M$10.12M-1.15330Upcoming EarningsPositive NewsGap Down Related Companies and Tools Related Companies ERAS Competitors SANA Competitors ZVRA Competitors ALT Competitors SNDL Competitors ORKA Competitors KMDA Competitors RVNC Competitors TECX Competitors AUTL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZNTL) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZNTL Stock Free ZNTL Stock Alerts